Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

Rhea-AI Summary

Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its upcoming participation in the Stifel 2025 Virtual CNS Forum. The company's management will deliver a corporate overview presentation on Tuesday, March 18, 2025, at 3:00 pm ET.

Interested parties can access a live audio webcast of the presentation through the Investors section of Alnylam's website at www.alnylam.com/events. A replay of the presentation will be made available on the company's website within 48 hours following the event.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 3:00 pm ET.

A live audio webcast of the presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), AMVUTTRA^® (vutrisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), and Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250311789872/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

When is Alnylam (ALNY) presenting at the Stifel 2025 Virtual CNS Forum?

Alnylam will present on Tuesday, March 18, 2025, at 3:00 pm ET.

How can investors watch Alnylam's (ALNY) Stifel CNS Forum presentation?

Investors can watch via live audio webcast on Alnylam's website at www.alnylam.com/events.

When will the replay of ALNY's Stifel 2025 presentation be available?

The replay will be available on Alnylam's website within 48 hours after the event.

What type of presentation will ALNY give at the Stifel 2025 Virtual CNS Forum?

Management will present a company overview at the forum.